BioPharm International integrates the science and business of biopharmaceuticals through print and online publications.
BioPharm International integrates the science and business of biopharmaceuticals, covering all aspects of biopharmaceutical research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging, as well as business strategies and regulatory issues.
Through a monthly print publication, website with daily updates, weekly and monthly newsletters, ebooks, webcasts, interviews, and special issues, the editors provide practical, peer-reviewed technical solutions to enable biopharmaceutical professionals to perform their jobs more effectively.
View the Editorial Calendar and Submission Guidelines
Contact the BioPharm International Editors
Submit an Online Request to the Editor
Submit Press Releases to BPpress@mmhgroup.com
A range of marketing options provide access to BioPharm International’s targeted audience of professionals involved in all stages of the development and manufacturing of biopharmaceutical therapeutics. Options include print and digital advertising, newsletter advertising, mail lists, webcasts, video programs, content marketing, and custom programs.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.